Evidence map›Paper›PMID 40481718›Full record

ArticleJournal of medical virology2025

High-Dimensional Immunophenotyping of Post-COVID-19 and Post-Influenza Patients Reveals Persistent and Specific Immune Signatures After Acute Respiratory Infection.

Francisco Pérez-Cózar, Paloma Cal-Sabater, Paulina Rybakowska, Elisa Arribas-Rodríguez, Aida Fiz-López, Antonio García-Blesa, Juan Hernández, Sara Gutiérrez, Pablo Tellería, Cristina Novoa and 17 more

Abstract read
In one paragraph

Article in Journal of medical virology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

27 authors.

Francisco Pérez-CózarPfizer-University of Granada-Junta de Andalucía Centre for Genomics and Oncological Research (GENYO). Pfizer/University of Granada/Andalusian Regional Government, PTS Granada, Granada, Spain.
Paloma Cal-SabaterMucosal Immunology Lab. Institute of Biomedicine and Molecular Genetics (IBGM, University of Valladolid-CSIC), Valladolid, Spain.
Paulina RybakowskaPfizer-University of Granada-Junta de Andalucía Centre for Genomics and Oncological Research (GENYO). Pfizer/University of Granada/Andalusian Regional Government, PTS Granada, Granada, Spain.
Elisa Arribas-RodríguezMucosal Immunology Lab. Institute of Biomedicine and Molecular Genetics (IBGM, University of Valladolid-CSIC), Valladolid, Spain.
Aida Fiz-LópezMucosal Immunology Lab. Institute of Biomedicine and Molecular Genetics (IBGM, University of Valladolid-CSIC), Valladolid, Spain.
Antonio García-BlesaMucosal Immunology Lab. Institute of Biomedicine and Molecular Genetics (IBGM, University of Valladolid-CSIC), Valladolid, Spain.
Juan HernándezMucosal Immunology Lab. Institute of Biomedicine and Molecular Genetics (IBGM, University of Valladolid-CSIC), Valladolid, Spain.
Sara GutiérrezInternal Medicine Department, Hospital Clínico Universitario de Valladolid, Valladolid, Spain.
Pablo TelleríaInternal Medicine Department, Hospital Clínico Universitario de Valladolid, Valladolid, Spain.
Cristina NovoaInternal Medicine Department, Hospital Clínico Universitario de Valladolid, Valladolid, Spain.
Silvia Rojo RelloMicrobiology Unit, Hospital Clínico Universitario de Valladolid, Valladolid, Spain.
Ángel De PradoMucosal Immunology Lab. Institute of Biomedicine and Molecular Genetics (IBGM, University of Valladolid-CSIC), Valladolid, Spain.
Cándido PérezMucosal Immunology Lab. Institute of Biomedicine and Molecular Genetics (IBGM, University of Valladolid-CSIC), Valladolid, Spain.
Rosa SedanoInternal Medicine Department, Hospital Clínico Universitario de Valladolid, Valladolid, Spain.
Marta Domínguez-GilMicrobiology Department, Hospital Universitario Rio Hortega, Valladolid, Spain.
María Jesús PeñarrubiaDepartment of Hematology, Hospital Clínico Universitario de Valladolid, Valladolid, Spain.
Daan K J PierenCentre for Infectious Disease Control, National Institute for Public Health and the Environment, Bilthoven, The Netherlands.
José A GarroteMucosal Immunology Lab. Institute of Biomedicine and Molecular Genetics (IBGM, University of Valladolid-CSIC), Valladolid, Spain.
Eduardo ArranzMucosal Immunology Lab. Institute of Biomedicine and Molecular Genetics (IBGM, University of Valladolid-CSIC), Valladolid, Spain.
José María EirosMicrobiology Unit, Hospital Clínico Universitario de Valladolid, Valladolid, Spain.
Eduardo TamayoDepartment of Surgery, Faculty of Medicine, Centro de Investigación Biomédica en Red de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III, Madrid, Universidad de Valladolid, Valladolid, Spain.
Antonio OrduñaMicrobiology Department, Hospital Universitario Rio Hortega, Valladolid, Spain.
Cécile A C M van ElsCentre for Infectious Disease Control, National Institute for Public Health and the Environment, Bilthoven, The Netherlands.
Carlos DueñasInternal Medicine Department, Hospital Clínico Universitario de Valladolid, Valladolid, Spain.
Concepción MarañónPfizer-University of Granada-Junta de Andalucía Centre for Genomics and Oncological Research (GENYO). Pfizer/University of Granada/Andalusian Regional Government, PTS Granada, Granada, Spain.
David BernardoMucosal Immunology Lab, Department of Paediatrics and Immunology, University of Valladolid, Valladolid, Spain.
Sara Cuesta-SanchoMucosal Immunology Lab, Department of Paediatrics and Immunology, University of Valladolid, Valladolid, Spain.ORCID 0000-0002-9890-1063

Funding

This study has been funded through Programa Estratégico Instituto de Biomedicina y Genética Molecular (IBGM Junta de Castilla y León. Ref. CCVC8485), Junta de Castilla y León (Proyectos COVID 07.04.467B04.74011.0) and the European Commission-NextGenerationEU (Regulation EU 2020/2094), through CSIC's Global Health Platform (PTI Salud Global: SGL21-03-026, SGL2021-03-038, COVID-19-117 and SGL2103015).
6 · The paper itself

Abstract

Long-term consequences of SARS-CoV-2 infection are unknown since recovered individuals can experience symptoms and latent viral reactivation for months. Indeed, acute post-infection sequelae have also been observed in other respiratory viral infections, including influenza. To characterize post-COVID-19 and post-influenza induced alterations to the cellular immunome, peripheral blood mononuclear cells (PBMCs) were obtained from patients 3 months after recovery from COVID-19 (n = 93) or influenza (n = 25), and from pre-pandemic healthy controls (n = 25). PBMCs were characterized using a 40-plex mass cytometry panel. Principal component analysis (PCA), classification models, and K-means clustering were subsequently applied. PCA identified distinct immune profiles between cohorts, with both post-COVID and post-flu patients displaying an altered chemokine receptor expression compared to pre-pandemic healthy controls. These alterations were more prominent in post-COVID patients since they exhibited highly increased expression of chemokine receptors CXCR3 and CCR6 by various lymphoid populations, while post-influenza patients mainly showed a decrease in CCR4 expression by naïve T cells, monocytes, and conventional dendritic cells. Classification models using immunophenotyping data confirm the three groups, while K-means clustering revealed two subgroups among post-COVID patients, with younger patients showing more pronounced immune alterations in the chemokine receptor profile, independently of long COVID symptoms. In conclusion, post-COVID and post-influenza patients exhibit distinct and unique persistent immune alterations. Understanding these altered immune profiles can guide targeted therapies for post-COVID syndrome and highlight differences in immune recovery from various respiratory infections.

Indexed as

COVID-19Influenza, HumanRespiratory Tract InfectionsAdultAgedFemaleHumansImmunophenotypingLeukocytes, MononuclearMaleMiddle AgedPost-Acute COVID-19 SyndromeSARS-CoV-2immune signatureimmunomepost‐COVID‐19post‐influenza

Identifiers

PMID40481718
PMCPMC12144678

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.